NCT03488251View on ClinicalTrials.gov

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Non-hodgkin Lymphoma,B CellRefractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell Lymphoma
Interventions
DRUG

MT-3724

MT-3724 will be administered.

DRUG

Gemcitabine

Gemcitabine will be administered.

DRUG

Oxaliplatin

Oxaliplatin will be administered.

Trial Locations (9)

21201

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

27710

Duke Cancer Center, Durham

45220

Good Samaritan Hospital, Cincinnati

46237

Indiana Blood and Marrow Transplantation, Indianapolis

60612

Rush University, Chicago

75390

UT Southwestern Medical Center Clinical Research, Dallas

90403

Sarcoma Oncology, Santa Monica

90603

Innovative Clinical Research Institute, Whittier

92868

UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange

Sponsors
All Listed Sponsors
lead

Molecular Templates, Inc.

INDUSTRY